Home > Journals > Acta Phlebologica > Past Issues > Acta Phlebologica 2017 August;18(2) > Acta Phlebologica 2017 August;18(2):52-6

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Acta Phlebologica 2017 August;18(2):52-6

DOI: 10.23736/S1593-232X.17.00394-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Biomarkers for precision medicine in phlebology and wound care: a systematic review

Raffaele SERRA 1, 2 , Nicola IELAPI 1, Andrea BARBETTA 1, Gianluca BUFFONE 1, Egidio BEVACQUA 1, Michele ANDREUCCI 3, Stefano de FRANCISCIS 1, 2, Vincenzo GASBARRO 1, 4

1 Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, Magna Græecia University, Catanzaro, Italy; 2 Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy; 3 Department of Health Sciences, University of Catanzaro, Catanzaro, Italy; 4 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy


PDF


INTRODUCTION: Precision medicine (PM) represents a tailored management based on specific patient biological and medical characteristics, at a highly detailed level, including disease screening, monitoring relapse and/or recurrence, selection and/or prediction of effective drug and/or surgical treatment. PM may be applied to Phlebology and Wound Care area and the aim of this review is to analyze the most updated information on this topic.
EVIDENCE ACQUISITION: The following key words were used to search the literature: “precision medicine and phlebology/venous disease,” “precision medicine and wound care,” “biomarkers and phlebology/venous disease,” “biomarkers and wound care.” All of those studies which did not fit the query or which reported insufficient data were excluded.
EVIDENCE SYNTHESIS: Of the 6845 records yielded by the search, after duplicate removing and after excluded records in title and abstract, 250 articles were left, which matched fulfilled the inclusion criteria. After reading the articles in full text, 203 were excluded because: 1) not responding properly to our research questions; 2) insufficient data; the final set included 47 articles.
CONCLUSIONS: In the context of phlebology and wound care, PM, through the use of measurable biomarkers coming from omics analysis, may be used in selecting the appropriate treatment, in evaluating response to treatment, and in monitoring recurrences. Thus, a tailored medical approach to patients with vein and chronic wound disease may be useful in order lower the high incidence of important clinical conditions that have great socio-economic impact on the general population.


KEY WORDS: Precision medicine - Biomarkers - Phlebology - Wounds and injuries - Evidence-based medicine

top of page